Savior LLC Reduces Stock Position in AbbVie Inc. (NYSE:ABBV)

Savior LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBVGet Rating) by 27.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200 shares of the company’s stock after selling 74 shares during the quarter. Savior LLC’s holdings in AbbVie were worth $33,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in AbbVie in the 4th quarter valued at about $2,433,269,000. State Street Corp grew its holdings in AbbVie by 3.4% in the 4th quarter. State Street Corp now owns 79,357,705 shares of the company’s stock valued at $10,745,033,000 after buying an additional 2,597,076 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of AbbVie in the 4th quarter valued at about $272,868,000. Capital International Investors lifted its stake in shares of AbbVie by 19.7% in the 4th quarter. Capital International Investors now owns 11,615,068 shares of the company’s stock valued at $1,572,680,000 after purchasing an additional 1,913,451 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of AbbVie by 51.2% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 5,533,034 shares of the company’s stock valued at $752,074,000 after purchasing an additional 1,874,609 shares in the last quarter. Hedge funds and other institutional investors own 67.03% of the company’s stock.

Shares of ABBV opened at $147.56 on Thursday. The company has a market cap of $260.75 billion, a P/E ratio of 21.17, a PEG ratio of 4.04 and a beta of 0.83. The stock has a fifty day moving average price of $150.17 and a 200 day moving average price of $146.18. The company has a debt-to-equity ratio of 3.89, a current ratio of 0.82 and a quick ratio of 0.71. AbbVie Inc. has a 12 month low of $105.56 and a 12 month high of $175.91.

AbbVie (NYSE:ABBVGet Rating) last issued its quarterly earnings data on Friday, April 29th. The company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $3.15 by $0.01. The firm had revenue of $13.36 billion during the quarter, compared to the consensus estimate of $13.61 billion. AbbVie had a return on equity of 159.31% and a net margin of 22.00%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.95 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.02 earnings per share for the current year.

ABBV has been the topic of several research analyst reports. Wells Fargo & Company lifted their price objective on AbbVie from $165.00 to $200.00 in a research note on Monday, May 2nd. Barclays boosted their price target on AbbVie from $150.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. Citigroup boosted their price target on AbbVie from $155.00 to $170.00 in a research report on Tuesday, March 1st. StockNews.com raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 8th. Finally, BMO Capital Markets boosted their price target on AbbVie from $161.00 to $174.00 and gave the stock an “outperform” rating in a research report on Monday, April 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $159.75.

In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the completion of the transaction, the executive vice president now owns 16,623 shares in the company, valued at approximately $2,576,565. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Vice Chairman Michael Severino sold 100,000 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $154.45, for a total value of $15,445,000.00. Following the transaction, the insider now owns 152,103 shares of the company’s stock, valued at approximately $23,492,308.35. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 463,761 shares of company stock valued at $70,609,771. 0.08% of the stock is owned by company insiders.

AbbVie Profile (Get Rating)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

See Also

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.